2015 has been a turbulent year for pharma stocks. Deals have helped the sector remain in favor, but concerns about pricing and the Valeant scandal are just two of the factors that have tarred the sector's reputation, bringing valuations back down to earth.
Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger
Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway.
Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK.
Rupert covers everything value investing for ValueWalk
Finance Mythbuster: Is Economic Growth Good for Investors? by Wesley R. Gray, Ph.D., Alpha Architect Author, Quantitative Value: A Practitioner’s Guide to Automating Intelligent Investment and Eliminating Behavioral Errors
Is Economic Growth... Read More
Former CalPers CEO Fred Buenrostro, one time investment chief at the US’s largest state pension fund, is admitting to a pay-for-play scandal and is implicating his one-time collaborator.
Former Calpers... Read More
Despite a recent record distribution of capital, if GPs continue to find attractive exit routes, then high distribution levels are likely to continue for some time, notes Preqin.
Preqin in... Read More